Advances in Universal Influenza Vaccines and Therapies

Dear Colleagues,

Seasonal and emerging influenza viruses have major implications for public health. Seasonal influenza A and B viruses are associated with high rates of illness and hospitalization each year, and vaccine strategies vary in efficacy year to year. Additionally, influenza viruses can lead to (and, in fact, have led to) pandemics, and the development of new, innovative strategies to improve protection against both seasonal and pandemic influenza viruses remains a high priority. The production of universal influenza vaccines and therapies is multifaceted, with numerous involved components under investigation, such as several vaccine candidates, adjuvants, vaccine platforms, small-molecule drugs, protein inhibitors, broadly reactive monoclonal antibodies, and influenza-specific immune responses.

This Special Issue aims to describe recent strategies that target influenza with vaccines and to understand and predict the corresponding immunological responses. Subtopics of interest include, but are not limited to:

• Influenza A and B virus vaccines;
• Full-length and engineered forms of viral antigens;
• General and high-risk host populations;
• Universal influenza vaccine design;
• Conventional and novel antigens;
• Conventional and novel platforms for vaccine development;
• Conventional and novel adjuvants/ formulations/ routes and technologies for delivery;
• Immune effectors/mechanisms and correlates of protection.

Dr. Charles J. Russell
Dr. Julia L. Hurwitz
Dr. Jarrod J. Mousa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.